Sanofi plays catch-up in immuno-oncology with new Regeneron deal
This article was originally published in Scrip
With their first collaboration producing the potential blockbuster Praluent and other near-market medicines, Sanofi and Regeneron are likely hoping they can repeat the trick with a new $2bn-deal covering immune-oncology.
You may also be interested in...
Constantine Chinoporos, Boston Pharmaceuticals’ CBO, talks to Scrip about its deal strategy and how it intends to build its pipeline over the next few years, liberated from the constraints of portfolio management.
Losing Medivation could end up being a winning proposition for the French pharma if it can boost its cancer franchise another way, like by acquiring its partner in multiple collaborations Regeneron or making a less expensive takeout, such as Incyte or Ariad.
Doesn't every biopharma company have an immuno-oncology strategy these days? It certainly seems that way, considering the number of drug developers that are labeling their therapeutic candidates as immunotherapies regardless of whether the description truly fits their asset.